Gain Therapeutics, Inc. (GANX) NASDAQ
1.83
-0.13(-6.63%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Gain Therapeutics, Inc.
Address
4800 Montgomery Lane
Bethesda, MD 20814
United States of America (the)
Phone
301 500 1556
Sector
Healthcare
Industry
Biotechnology
Employees
23
First IPO Date
March 19, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Gene Mack | President, Chief Executive Officer & Director | 664,320 | 1974 |
| Khalid Islam | Chairman & Founder | 75,000 | 1955 |
| Gianluca Fuggetta | Senior Vice President of Finance & Principal Financial Officer | 263,074 | 1989 |
| Joanne Taylor | Senior Vice President of Research | 0 | N/A |
| Jonas Hannestad | Chief Medical Officer | 0 | N/A |
| Terenzio Ignoni | Senior Vice President of Technical Operations | 0 | N/A |
Description
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
